| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Product containing oxytocin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Lypressin (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Oxytocic preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Desmopressin acetate 10micrograms nasal spray (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Desmopressin acetate 100 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely desmopressin acetate 200 microgram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Desmopressin acetate 100micrograms/1mL intranasal solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| acétate de desmopressine 4 microgrammes/mL, ampoule de 1 mL de solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing terlipressin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Terlipressin 1mg injection (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Vasopressin 20iu/1mL injection (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely ergometrine maleate 500 microgram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ergometrine maleate 500micrograms/1mL injection (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ergometrine maleate+oxytocin 500micrograms/5units/1mL injection (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Oxytocin 5units/1mL injection (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Oxytocin 10units/1mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing ergometrine and oxytocin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Antidiuretic hormone product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ergonovine maleate 200mcg/mL inejction solution ampoule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Desmopressin acetate 1.5mg/mL spray |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Methylergonovine maleate 0.2mg/mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Desmopressin acetate 0.01% solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Oxytocin 10unt/mL injection (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Vasopressin 20unt/mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Desmopressin acetate 0.1mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Desmopressin acetate 0.2mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Desmopressin acetate 0.1mg/mL solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Desmopressin acetate 0.01% spray |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Methylergonovine maleate 0.2mg/cc |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely methylergometrine maleate 20 microgram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Urea 40-50% injection solution vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing posterior pituitary hormone (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing methylergometrine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing desmopressin acetate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Methylergonovine maleate preparation (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing vasopressin tannate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing ergometrine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing vasopressin |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Desmopressin-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Lypressin preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ergonovine maleate preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Vasopressin 20unt/mL injection solution 10mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Vasopressin 20unt/mL injection solution 0.5mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Vasopressin 20unt/mL injection solution 1mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing ergometrine maleate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dinoprostone 10mg pessary (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely dinoprostone 500 microgram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| dinoprostone 1 mg/mL, ampoule de 0,75 mL de concentré pour perfusion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| dinoprostone 10 mg/mL, ampoule de 0,5 mL de concentré pour perfusion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dinoprostone 5mg/0.5mL extra-amniotic solution+diluent (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dinoprostone 400 microgram/mL vaginal gel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely dinoprostone 800 microgram/1 milliliter conventional release vaginal gel (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dinoprostone 3 mg vaginal tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Mifepristone 200mg tablet (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Oral dinoprostone (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dinoprostone-containing product in parenteral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing dinoprostone in vaginal dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing dinoprostone (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing mifepristone (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dinoprostone 10mg insert |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Oxytocin |
Is a |
True |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Antidiuretic hormone |
Is a |
True |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Adverse reaction to posterior pituitary hormones |
Causative agent (attribute) |
True |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Adverse reaction to posterior pituitary hormone NOS |
Causative agent (attribute) |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Posterior pituitary hormone poisoning NOS |
Causative agent (attribute) |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Poisoning by posterior pituitary hormone |
Causative agent (attribute) |
True |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Lypressin adverse reaction (disorder) |
Causative agent (attribute) |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Accidental vasopressin poisoning |
Causative agent (attribute) |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Adverse reaction caused by antidiuretic hormone (disorder) |
Causative agent (attribute) |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Desmopressin adverse reaction |
Causative agent (attribute) |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Terlipressin adverse reaction (disorder) |
Causative agent (attribute) |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Poisoning by vasopressin |
Causative agent (attribute) |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Intentional vasopressin poisoning |
Causative agent (attribute) |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Vasopressin poisoning of undetermined intent |
Causative agent (attribute) |
False |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Terlipressin acetate |
Is a |
True |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Lypressin (substance) |
Is a |
True |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Argipressin |
Is a |
True |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Vasopressin tannate (substance) |
Is a |
True |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Terlipressin (substance) |
Is a |
True |
Posterior pituitary hormone |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.4-SNAPSHOT
|
FHIR Version n/a
User: [n/a]